The importance of analytical quality specifications for biomarker assays currently used in acute cardiac care

Acute Cardiac Care

Volumn 8, Issue 3, 2006, Pages 133-138

  Panteghini, Mauro ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Myocardial infarction; Natriuretic peptides; Troponin

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; TROPONIN;

ACUTE CARDIAC CARE; ANALYTIC METHOD; ANALYTICAL PARAMETERS; ANTIBODY SPECIFICITY; ASSAY; CALIBRATOR; CLINICAL LABORATORY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; EMERGENCY CARE; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HUMAN; LABORATORY DIAGNOSIS; MEDICAL DECISION MAKING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPONSIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; UNITED STATES;

BIOLOGICAL ASSAY; BIOLOGICAL MARKERS; DIAGNOSTIC TECHNIQUES, CARDIOVASCULAR; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; QUALITY CONTROL; TROPONIN;

EID: 33749454326     PISSN: 17482941     EISSN: 1748295X     Source Type: Journal    
DOI: 10.1080/17482940600885451     Document Type: Review

References (26)

1. Panteghini M. Performance of today's cardiac troponin assays and tomorrow's. Clin Chem. 2002;48:809-10.
2. Panteghini M, Gerhardt W, Apple FS, Dati F, Ravkilde J, Wu AH. Quality specifications for cardiac troponin assays. International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). Clin Chem Lab Med. 2001;39:174-8.
3. Apple FS, Panteghini M, Ravkilde J, Mair J, Wu AHB, et al. Quality specification for B-type natriuretic peptide assays. Clin Chem. 2005;51:486-93.
4. Katrukha A, Bereznikova A, Pettersson K. New approach to standardization of human cardiac troponin I (cTnI). Scand J Clin Lab Invest. 1999;59(suppl 230):124-7.
5. Panteghini M, Forest JC. Standardization in laboratory medicine: new challenges. Clin Chim Acta. 2005;355:1-12.
6. Panteghini M. Standardization of cardiac troponin I measurements: the way forward? Clin Chem. 2005;51:1594-7.
7. Shi Q, Ling M, Zhang X, Zhang M, Kadijevic L, Liu S, et al. Degradation of cardiac troponin I in serum complicates comparisons of cardiac troponin I assays. Clin Chem. 1999;45:1018-25.
8. McDonough JL, Arrell DK, Van Eyk JE. Troponin I degradation and covalent complex formation accompanies myocardial ischemia/reperfusion injury. Circ Res. 1999;84:9-20.
9. Panteghini M. Selection of antibodies and epitopes for cardiac troponin immunoassays: should we revise our evidence-based beliefs? Clin Chem. 2005;51:803-4.
10. Eriksson S, Halenius H, Pulkki K, Hellman J, Pettersson K. Negative interference in cardiac troponin I immunoassays by circulating troponin autoantibodies. Clin Chem. 2005;51:839-47.
11. Shimizu H, Masuta K, Asada H, Sugita K, Sairenji T. Characterization of molecular forms of probrain natriuretic peptide in human plasma. Clin Chim Acta. 2003;334:233-9.
12. Brandt I, Lambeir AM, Ketelslegers JM, Vanderheyden M, Scharpé S, De Meester I. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem. 2006;52:82-7.
13. Ala-Kopsala M, Magga J, Peuhkurinen K, Leipala J, Ruskoaho H, et al. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B- type natriuretic peptides. Clin Chem. 2004;50:1576-88.
14. Storti S, Prontera C, Emdin M, Passino C, Prati P, et al. Analytical performance and clinical results of a fully automated MEIA system for BNP assay: comparison with a POCT method. Clin Chem Lab Med. 2004;42:1178-85.
15. Clerico A, Prontera C, Emdin M, Passino C, Storti S, et al. Analytical performance and diagnostic accuracy of immunometric assays for the measurement of plasma B-type natriuretic peptide (BNP) and N-terminal proBNP. Clin Chem. 2005;51:445-7.
16. Emdin M, Clerico A, Clemenza F, Galvani M, Latini R, et al. Recommendations for the clinical use of cardiac natriuretic peptides. Ital Heart J. 2005;6:430-46.
17. Ferguson JL, Beckett GJ, Stoddart M, Walker SW, Fox KAA. Myocardial infarction redefined: the new ACC/ESC definition, based on cardiac troponin, increases the apparent incidence of infarction. Heart. 2002;88:343-7.
18. Venge P, Lagerqvist B, Diderholm E, Lindahl B, Wallentin L. Clinical performance of three cardiac troponin assays in patients with unstable coronary artery disease (a FRISC II substudy). Am J Cardiol. 2002;89:1035-41.
19. Panteghini M, Pagani F, Yeo KTJ, Apple FS, Christenson RH, et al. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin Chem. 2004;50:327-32.
20. Sheehan P, Blennerhassett J, Vasikaran SD. Decision limit for troponin I and assay performance. Ann Clin Biochem. 2002;39:213-6.
21. Panteghini M, Clerico A. Cardiac natriuretic hormones as markers of cardiovascular disease: methodological aspects. In: Clerico A, Emdin M, editors. Natriuretic peptides. The hormones of the heart. Heidelberg, Germany: Springer, 2006. pp. 65-89.
22. Banerjee S, Linder MW, Singer I. False-positive troponin I in a patient with acute cholecystitis and positive rheumatoid factor assay. Cardiology. 2001;95:170-1.
23. Collinson PO, Barnes SC, Gaze DC, Galasko G, Lahiri A, Senior R. Analytical performance of the N terminal pro B type natriuretic peptide (NT-proBNP) assay on the Elecsys 1010 and 2010 analysers. Eur J Heart Fail. 2004;6:365-8.
24. Panteghini M. The measurement of cardiac markers. Where should we focus? Am J Clin Pathol. 2002;118:354-61.
25. Shimizu H, Aono K, Masuta K, Asada H, Misaki A, Teraoka H. Degradation of human brain natriuretic peptide (BNP) by contact activation of blood coagulation system. Clin Chim Acta. 2001;305:181-6.
26. Apple FS, Wu AHB, Mair J, Ravkilde J, Panteghini M, et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem. 2005;51:810-24.